One approach to treating Alzheimer's disease is to eliminate substances that cause the disease by stimulating specific areas of the brain. This is the strategy being pursued by the start-up Bottneuro, a spin-off from the University of Basel based at Technologiepark Basel. The company intends to establish a network of diagnostic centers for Alzheimer’s patients to offer personalized therapy approaches to those affected by the disease. The business magazine Forbes listed Bottneuro among the 30 best spin-offs situated in the German-speaking DACH (Germany, Austria and Switzerland) region to keep an eye on over the course of 2021.
For the development of its personalized therapy, Bottneuro is joining forces with Positrigo. The spin-off from the Swiss Federal Institute of Technology Zurich (ETH) specializes in the development of nuclear medicine imaging technologies. Bottneuro is planning to use a positron emission tomography (PET) device developed by Positrigo to accurately localize the correct areas of the brain to treat in Alzheimer’s patients.
The two start-ups have signed a Memorandum of Understanding (MoU) for the delivery of several NeuroLF-type brain PET imaging devices, Positrigo writes in a press release. These are to be delivered as soon as a CE mark is awarded to the NeuroLF. “We are delighted to agree this cooperation with Positrigo”, comments Bekim Osmani, Managing Director of Bottneuro, in the press release. “The NeuroLF brain PET device will enable us to offer cost-effective PET scans in our Alzheimer's diagnostic centers in order to obtain important 3D data sets that we need for our personalized Alzheimer's therapy”.
